Navigation Links
Olympus broadens portfolio with new biliary metallic stent
Date:6/1/2009

CENTER VALLEY, Pa., June 1, 2009 Olympus America Inc. today expanded its medical portfolio by introducing the X-Suit NIR, a biliary metallic stent designed with exceptional anatomic conformability and superior radial support. The X-Suit NIR's proprietary NIRflex cell design provides a physician support and flexibility; both critical to help relieve the symptoms associated with pancreatic, liver and bile duct cancers.

The NIRflex advanced cell design biliary metallic stent provides flexible construction to fit the shape of any biliary duct. Constructed of Nitinol, the stent is water-jet cut and electro-polished for much greater durability. Each strut is also rounded, helping to reduce stress to the tissue and prevent damage to the bile duct and duodenal walls.

"Olympus provides the most extensive line of GI products and services in the industry," said Eric Halvorson, chief marketing officer, Medical Systems Group, Olympus America, Inc. "X-Suit is a good example of how Olympus remains dedicated to expanding its offerings and working with the world's top medical experts to provide solutions that best suit the needs of its customers and their patients."

To ensure precise placement of the stent during a therapeutic procedure, the X-Suit NIR has virtually no foreshortening. In addition, each end of the stent features five radiopaque markers that allow physicians to determine the position of the stent under an X-ray prior to deployment. A black marker is positioned at the proximal end of the stent facilitating endoscopic confirmation of the stent during deployment. The ease of deployment combined with superior radial support makes the X-Suit NIR the stent of choice for re-establishing biliary flow.


'/>"/>

Contact: Lisa Koen
lkoen@golinharris.com
212-373-6099
Golin/Harris International
Source:Eurekalert  

Page: 1

Related biology news :

1. Olympus advances technology for laparo-endoscopic single-site surgery
2. Lockheed Martin Advances Biometrics Portfolio Through Cooperation Agreement With Cognitec
3. Springer expands its portfolio in plant sciences with Phytoparasitica
4. 2 carotid artery stenting studies show results comparable to AHA guidelines
5. Massive California fires consistent with climate change
6. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
7. Persistent man-made chemical pollutants found in deep-sea octopods and squids
8. Stent grafts: a better way to treat blunt trauma injuries
9. Goulbourne earns NSF award to research heart stent sensors
10. 12-month ATLANTA trial data show sustained benefit of Catania Stent
11. Persistent pollutant may promote obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Olympus broadens portfolio with new biliary metallic stent
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... the licensing, development and commercialization of innovative biopharmaceutical products ... Company in North America 2016. ... based on the FDA approval of three innovative ... ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... -- Ginkgo Bioworks, the organism company, announced today ... synthesis and assembly of DNA. The acquisition will ... DNA into Ginkgo,s automated organism engineering foundries, enabling ... new organism designs for application across a wide ... to significantly increase the world,s capacity to cost-effectively ...
(Date:1/19/2017)... , Jan. 19, 2017  Market Research Future has a half ... for Liquid Biopsy is growing rapidly and expected to reach USD ... Market Highlights ... Global Liquid Biopsy Market has been assessed as a swiftly growing ... and boom in the coming future. There has been a tremendous ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... software solutions for pharmaceutical research and development (R&D), today announced the launch ... data analysis and interpretation for the rapidly evolving field of precision medicine. ...
Breaking Biology Technology: